Variable cytotoxicity of amifostine in malignant and non-malignant cell lines

被引:5
|
作者
Brenner, B
Wasserman, L
Beery, E
Nordenberg, J
Schechter, J
Gutman, H
Fenig, E
机构
[1] Rabin Med Ctr, Inst Oncol, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Felsenstein Med Res Inst, IL-49100 Petah Tiqwa, Israel
[3] Rabin Med Ctr, Dept Surg B, IL-49100 Petah Tiqwa, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
amifostine; radioprotector; cytotoxicity; cell lines;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Amifostine is the best known radioprotector and chemoprotector which has already been incorporated into general oncology practice. However, the data regarding its action at the cellular level remain unclear. The present study examined the effect of amifostine with and without ionizing radiation on the growth of malignant and non-malignant cell lines. Amifostine was found to have a remarkable cytotoxic effect on malignant epithelial cell lines but a modest cytotoxic effect on malignant melanoma and non-malignant cell lines. It demonstrated an additive effect with radiation therapy on the malignant cell line and a variable effect on the non-Malignant cell line. Endothelial cells were not affected by amifostine, but the myoblast cells showed a synergistic effect of amifostine and radiation. These findings demonstrate that the cytotoxic as well as the radioprotective effect of amifostine are cell-specific. Thus, caution should be exercised in the use of amifostine as a radioprotector, and it should be tested for each model of disease.
引用
收藏
页码:1609 / 1613
页数:5
相关论文
共 50 条
  • [21] Neurological manifestations of malignant and non-malignant dysglobulinaemias
    Steck, AJ
    JOURNAL OF NEUROLOGY, 1998, 245 (10) : 634 - 639
  • [22] Biomarkers and imaging in non-malignant and malignant osteomalacia
    Lüftner, D
    Bollow, M
    Stürzenbecher, A
    Kaufmann, O
    Priem, F
    Richter, A
    Günther, S
    Geppert, R
    Petrides, PE
    Wernecke, KD
    Possinger, K
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02): : 136 - 141
  • [23] Radium treatment of malignant and non-malignant diseases
    不详
    BRITISH MEDICAL JOURNAL, 1929, 1929 (02): : 551 - 552
  • [24] LEUCOCYTOTOXICITY IN MALIGNANT AND NON-MALIGNANT COLONIC DISEASES
    VOSE, BM
    MOORE, M
    SCHOFIELD, PF
    DYMOCK, IW
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1975, 22 (03): : 393 - 398
  • [25] The endoscopist and malignant and non-malignant biliary obstruction
    Pereira, S. P.
    Goodchild, G.
    Webster, G. J. M.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (04): : 1478 - 1483
  • [26] Neurological manifestations of malignant and non-malignant dysglobulinaemias
    Andreas J. Steck
    Journal of Neurology, 1998, 245 : 634 - 639
  • [27] LEUCOCYTOTOXICITY IN MALIGNANT AND NON-MALIGNANT COLONIC DISEASES
    VOSE, BM
    MOORE, M
    SCHOFIELD, PF
    DYMOCK, IW
    BRITISH JOURNAL OF CANCER, 1975, 32 (02) : 244 - 245
  • [28] Different glycosylation of cadherins from human bladder non-malignant and cancer cell lines
    Przybyło M.
    Hoja-Lukowicz D.
    Lityńska A.
    Laidler P.
    Cancer Cell International, 2 (1)
  • [29] Non-myeloablative stem cell transplantation (NST) for the treatment of malignant and non-malignant diseases
    Slavin, S
    Nagler, A
    Shapira, M
    Panigrahi, S
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 127 - 127
  • [30] Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders
    Shimoni, A
    Nagler, A
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (04): : 272 - 279